Back Home Next

From Press Release. April 22, 2004 08:30 AM US Eastern Timezone Daxor Corporation Announces a Study by the University of Miami/Jackson Memorial Hospital of Chronic Fatigue Syndrome Using the BVA-100

NEW YORK--(BUSINESS WIRE)--April 22, 2004--Daxor Corporation, (AMEX: DXR), a leading medical instrumentation and biotechnology company, today announced that the receipt of an agreement from the laboratory of Dr. Barry Hurwitz of the Behavioral Medicine Research Center, University of Miami, to use the BVA-100 Blood Volume Analyzer in conjunction with Jackson Memorial Hospital. The equipment will be used in the study of Chronic Fatigue Syndrome in the Department of Nuclear Medicine, under the supervision of Dr. George Sfakianakis, Chief of Nuclear Medicine at Jackson Memorial Hospital. The study will be conducted by Dr. Barry Hurwitz, Professor of Psychology, Medicine, and Biomedical Engineering at the Behavioral Medicine Research Center. The University of Miami is the largest, most comprehensive private research university in the southeastern United States with a well-earned reputation for academic excellence. The study is sponsored in part by the National Institutes of Health (NIH), National Heart, Lung and Blood Institute.

Included in the study will be investigation of the benefits of the use of epoetin alpha or PROCRIT, manufactured by Ortho Biotech Products, L.P., which increases the red blood cell volume of patients. This study will utilize the BVA-100 Blood Volume Analyzer, the only semi-automated instrument, and its associated kit, approved by the FDA.

The Chronic Fatigue Syndrome is said to affect over 1 million Americans. In its more severe forms it may be so disabling that individuals are unable to engage in normal activity, and many of them are on disability. Studies have suggested that susceptible individuals may experience sudden drops of blood pressure which may trigger fainting. A preliminary study has suggested that some of these individuals may suffer from low blood volume, which cannot be detected by the standard tests such as hematocrit or hemoglobin used to detect anemia. Low blood volume, and particularly low red cell volume, may cause an individual to be susceptible to feelings of weakness and fatigue. It is well known that patients who are significantly red cell volume depleted may have profound symptoms of weakness. This study will evaluate the frequency to which low blood volume plays a role in the Chronic Fatigue Syndrome and the extent to which its treatment will ameliorate the symptoms.

Dr. Joseph Feldschuh, President of Daxor, stated that "We are pleased that a distinguished university such as the University of Miami will be utilizing the BVA-100 in this important research work."

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit. It is the first instrument to provide rapid, direct measurement of a patient's blood volume with a high degree of precision. Among nationally renowned hospitals which have purchased the BVA-100 Blood Volume Analyzer are the Mayo Clinic, the Cleveland Clinic, NIH, and New York University Medical Center, as well as other major medical institutions. Among the other conditions in which the blood volume analyzer has been used are congestive heart failure, syncope, and septic shock. More information about the BVA-100 and other Daxor products and services can be found at